- USD/CAD stays defensive around one-week low, mildly bid on a day.
- Oil bulls take a breather at the monthly top.
- Mixed updates over Omicron, US stimulus join holiday mood to restrict market moves.
USD/CAD bounces off 20-DMA to consolidate weekly losses around 1.2815, up 0.10% intraday during early Friday.
The loonie pair tracks a pause in the prices of Canada’s key export item WTI crude oil to print the latest corrective pullback. However, lackluster markets during the holiday season challenge the moves of late.
That said, Thursday’s firmer US Treasury yields and upbeat prints of the Fed’s preferred gauge of inflation, namely the Core PCE Price Index, seemed to have prepared the based for the USD/CAD buyer’s return. It should be noted that Canadian GDP matched 0.8% upbeat forecasts, versus 0.2% upwardly revised prior, for October.
In addition to the firmer US data, indecision over the Omicron conditions and US stimulus also challenge the pair’s further downside.
The US Food and Drug Administration (FDA) also approved Merck's Covid-19 pill on Thursday, a day after approving Pfizer’s pill to battle the Omicron on Wednesday. Earlier in the week, US Military also conveyed news of developing a single cure for covid and all variants. Also on the positive side were the studies showing Omicron has lesser scope hospitalization. On the contrary, the French cancellation of orders for Merck’s pill, citing notably lesser effect than promoted, joins a steady rise in Omicron cases to challenge the market optimism.
Elsewhere, US President Joe Biden and House Speaker Nancy Pelosi remain hopeful of getting the Build Back Better (BBB) plan through the House even as Senator Joe Manchin opposes the bill. As per the latest news from CNN, “Sen. Joe Manchin effectively put an end to negotiations over the current version of the Build Back Better Act, in part over concerns that some provisions might exacerbate inflation. But many economists believe its effect on inflation would be marginal.”
Amid these plays, the US 10-year Treasury yields refreshed monthly high and the Wall Street benchmarks also posted gains. However, the Asia-Pacific stocks are lackluster by the press time.
Given the off in most of the Western markets and a light calendar, the USD/CAD prices are expected to remain sidelined amid a lack of major data/events.
Although the 20-DMA restricts the immediate downside of the USD/CAD prices near the 1.2800 round figure, a clear break of an upward sloping trend line from December 08, close to 1.2885, tests the quote’s rebound.
Additional important levels
|Today last price||1.2818|
|Today Daily Change||0.0014|
|Today Daily Change %||0.11%|
|Today daily open||1.2804|
|Previous Daily High||1.2854|
|Previous Daily Low||1.2798|
|Previous Weekly High||1.2937|
|Previous Weekly Low||1.2706|
|Previous Monthly High||1.2837|
|Previous Monthly Low||1.2352|
|Daily Fibonacci 38.2%||1.2819|
|Daily Fibonacci 61.8%||1.2832|
|Daily Pivot Point S1||1.2783|
|Daily Pivot Point S2||1.2763|
|Daily Pivot Point S3||1.2728|
|Daily Pivot Point R1||1.2839|
|Daily Pivot Point R2||1.2874|
|Daily Pivot Point R3||1.2895|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.